

**HMDS TESTS NOT CURRENTLY INCLUDED IN SCOPE OF  
UKAS ACCREDITATION**

TEST NAME	Date submitted for addition to scope	Addition to scope granted
<b>Molecular Genetics:</b>		
Multiplex Ligation-dependent Probe Amplification (MLPA) for copy number abnormalities in myeloma	21/07/2017	18/12/2017
Multiplex Ligation-dependent Probe Amplification (MLPA) for copy number abnormalities in CLL	21/07/2017	18/12/2017
EZH2 mutational analysis (prognostic)	21/07/2017	18/12/2017
FGFR3 gene rearrangement in myeloma	21/07/2017	09/12/2017
PML-RARa fusion genes in suspected acute promyelocytic leukaemia (APML) cases (FAST-FISH protocol)	21/07/2017	09/12/2017
DUSP22/IRF4 gene rearrangements in anaplastic large T cell lymphoma and DLBCL	21/07/2017	09/12/2017
TP63 gene rearrangements in anaplastic large T cell lymphoma	21/07/2017	09/12/2017
CEBP alpha testing	31/05/2018 - pending accreditation	
CLL marginal zone HTS panel	31/05/2018 - pending accreditation	
11q gain/loss probe; secondary panel in high grade lymphoma with normal FISH	31/05/2018 - pending accreditation	
Automated RNA extraction using Maxwell RSC instrument.	31/05/2018 - pending accreditation	
MECOM breakapart FISH probe	31/05/2018 - pending accreditation	

<b>Flow Cytometry:</b>		
Addition of antigens to the Stem Cell Screen (6-clr to 8-clr) for use in MDS/cytopenia	21/07/2017	7/12/2017
Addition of antigens to the Plasma Cell Screen (6-clr to 8-clr) for diagnosis and monitoring of myeloma and related disorders	21/07/2017	7/12/2017

<b>Histopathology:</b>		
LMO2 by immunohistochemistry (for Germinal Centre B-cells and related lymphomas)	31/05/2018 - pending accreditation	
CD13 by immunohistochemistry	31/05/2018 - pending accreditation	
CD33 by immunohistochemistry	31/05/2018 - pending accreditation	
HDCA2 by immunohistochemistry (for Germinal Centre B-cells and related lymphomas)	Not yet submitted (validation on-going)	

